NO20010960L - Alginatkapsler til bruk ved behandling av hjernesvulster - Google Patents

Alginatkapsler til bruk ved behandling av hjernesvulster

Info

Publication number
NO20010960L
NO20010960L NO20010960A NO20010960A NO20010960L NO 20010960 L NO20010960 L NO 20010960L NO 20010960 A NO20010960 A NO 20010960A NO 20010960 A NO20010960 A NO 20010960A NO 20010960 L NO20010960 L NO 20010960L
Authority
NO
Norway
Prior art keywords
treatment
brain tumors
alginate capsules
alginate
capsules
Prior art date
Application number
NO20010960A
Other languages
English (en)
Other versions
NO20010960D0 (no
Inventor
Rolf Bjerkvig
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Priority to NO20010960A priority Critical patent/NO20010960L/no
Publication of NO20010960D0 publication Critical patent/NO20010960D0/no
Publication of NO20010960L publication Critical patent/NO20010960L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20010960A 1998-08-26 2001-02-26 Alginatkapsler til bruk ved behandling av hjernesvulster NO20010960L (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20010960A NO20010960L (no) 1998-08-26 2001-02-26 Alginatkapsler til bruk ved behandling av hjernesvulster

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO983911A NO983911D0 (no) 1998-08-26 1998-08-26 Alginatkapsler til bruk ved behandling av hjernesvulst
PCT/NO1999/000266 WO2000012066A1 (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour
NO20010960A NO20010960L (no) 1998-08-26 2001-02-26 Alginatkapsler til bruk ved behandling av hjernesvulster

Publications (2)

Publication Number Publication Date
NO20010960D0 NO20010960D0 (no) 2001-02-26
NO20010960L true NO20010960L (no) 2001-04-25

Family

ID=19902361

Family Applications (2)

Application Number Title Priority Date Filing Date
NO983911A NO983911D0 (no) 1998-08-26 1998-08-26 Alginatkapsler til bruk ved behandling av hjernesvulst
NO20010960A NO20010960L (no) 1998-08-26 2001-02-26 Alginatkapsler til bruk ved behandling av hjernesvulster

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO983911A NO983911D0 (no) 1998-08-26 1998-08-26 Alginatkapsler til bruk ved behandling av hjernesvulst

Country Status (16)

Country Link
US (2) US6926888B1 (no)
EP (1) EP1105100A1 (no)
JP (1) JP2002523445A (no)
KR (1) KR100699286B1 (no)
CN (1) CN1191823C (no)
AU (1) AU760433B2 (no)
BR (1) BR9913326A (no)
CA (1) CA2340325A1 (no)
IL (2) IL141501A0 (no)
IS (1) IS5855A (no)
NO (2) NO983911D0 (no)
NZ (1) NZ510167A (no)
RU (1) RU2229287C2 (no)
TR (1) TR200100583T2 (no)
WO (1) WO2000012066A1 (no)
ZA (1) ZA200101464B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1053329T3 (da) * 1998-02-03 2010-01-25 Ct Disease Contr & Prevention Rekombinant lipideret PsaA-protein, fremgangsmåder til fremstilling og anvendelse
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
RU2336901C1 (ru) * 2007-08-10 2008-10-27 Владимир Павлович Чехонин Противоопухолевое средство на основе иммунолипосомальной биологической конструкции, способ его получения и векторной доставки в центральную нервную систему при опухолевом процессе
KR100969516B1 (ko) * 2007-08-16 2010-07-09 경북대학교 산학협력단 세포 생존력 및 기능을 향상시키는 도우넛형 세포 캡슐의제조 방법 및 세포 치료적용
RU2422521C2 (ru) * 2009-07-31 2011-06-27 Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" Способ получения гранул, содержащих иммобилизованные нефтеокисляющие микроорганизмы
US9555007B2 (en) 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
CN118976106B (zh) * 2024-07-31 2025-12-09 湖南大学 一种藻酸盐基热遗传学cxcl12释放器及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5073491A (en) * 1988-12-23 1991-12-17 Hoffman-La Roche Inc. Immobilization of cells in alginate beads containing cavities for growth of cells in airlift bioreactors
US5459054A (en) * 1989-12-05 1995-10-17 Neocrin Company Cells encapsulated in alginate containing a high content of a- l- guluronic acid
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
CA2109085C (en) * 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
DK0769932T3 (da) 1994-07-08 1999-06-23 Baxter Int Implanteret indretning indeholdende tumorceller til behandling af cancer
US6126936A (en) * 1995-03-10 2000-10-03 Biohybrid Technologies Llc Microcapsules and composite microreactors for immunoisolation of cells
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
EP1382346B1 (en) 1996-04-03 2007-09-26 The Rogosin Institute Conditioned medium and diffusible biological product produced by incubating entrapped cells
WO1997038707A1 (en) * 1996-04-17 1997-10-23 Cytotherapeutics, Inc. Method and device for delivery of apoptosis-inducing molecules
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6368612B1 (en) * 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells

Also Published As

Publication number Publication date
KR100699286B1 (ko) 2007-03-26
BR9913326A (pt) 2001-05-15
US20050180960A1 (en) 2005-08-18
KR20010074851A (ko) 2001-08-09
CN1191823C (zh) 2005-03-09
EP1105100A1 (en) 2001-06-13
IL141501A (en) 2006-10-31
ZA200101464B (en) 2002-05-21
WO2000012066A1 (en) 2000-03-09
IL141501A0 (en) 2002-03-10
US6926888B1 (en) 2005-08-09
AU5538999A (en) 2000-03-21
IS5855A (is) 2001-02-22
NO983911D0 (no) 1998-08-26
CN1320032A (zh) 2001-10-31
RU2229287C2 (ru) 2004-05-27
NZ510167A (en) 2003-09-26
CA2340325A1 (en) 2000-03-09
AU760433B2 (en) 2003-05-15
TR200100583T2 (tr) 2001-06-21
NO20010960D0 (no) 2001-02-26
JP2002523445A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
NO991955L (no) FremgangsmÕte for behandling av hydrokarboner
NO984431L (no) FremgangsmÕte for behandling av smerte
NO20022087L (no) Fremgangsmåte for behandling av diabetes
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
NO20005885D0 (no) Kombinasjonsterapi for behandling av refraktær depresjon
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
EP1187604A4 (en) CONNECTIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS FAILURES
NO20010960L (no) Alginatkapsler til bruk ved behandling av hjernesvulster
NO984446D0 (no) FremgangsmÕte for behandling av smerte
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL141426A0 (en) Compositions and methods for the treatment of tumor
HUP0101947A3 (en) Combination for the treatment of tumors
NO994258L (no) Anvendelse av levobupivakain for behandling av ansiktsmigrene
IL147410A0 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc
AU2566201A (en) Compounds and methods for the treatment of pain
GB2341099B (en) Clinical table for treatment of the spine
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
AU2420201A (en) Compounds and methods for the treatment of pain
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application